The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)-Reply
Michele Mercuri, MD;
Vardaman M. Buckalew, Jr, MD;
Michael V. Rocco, MD;
M. Gene Bond, PhD
Bowman Gray School of Medicine Winston-Salem, NC
Patricia A. Borhani
University of Nevada, Reno
Maria Canossa-Terris, MD
Heart Research Institute Miami, Fla
Albert A. Carr, MD
Preventive Cardiology Inc Augusta, Ga
C. Tissa Kappagoda, MD
University of California at Davis
Harold W. Schnaper, MD
Scientific Application Co Inc Birmingham, Ala
James R. Sowers, MD
Wayne State University Detroit, Mich
JAMA. 1997;277(4):297-298.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In Reply.
—Regarding the comments by Dr Kaufman on the ultrasound data, the ultrasound instrument used in MIDAS was Biosound 2000 II spectrum analysis with 8-MHz annular arrays (approximate axial resolution, 0.3 mm). This was defined in the original protocol and previously published.1 Kaufman notes that the intimal-medial thickness differences in MIDAS are less than the axial resolution of ultrasound equipment, and therefore the analyses may overstate the ability of these instruments to determine the fine differences reported. The differences presented were calculated, not measured, by comparing within-group or between-group intimal-medial thickness data. That it is not possible to directly measure these differences does not affect the validity or appropriateness of determining their presence or use in analyses of grouped data.
The comments by Dr Abt concerning the statistical significance (or lack thereof) of the difference in cardiovascular events between patients treated with hydrochlorothiazide and isradipine in the MIDAS trial seem
. . . [Full Text PDF of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
